MIP was used in 30 eyes (53%), all with ME. IM treatment was successful in 22/30 eyes (73%). ME decrease and VA increased in 19/30 eyes (63.3%), with no ME recurrence during follow-up. The authors report their experience using 577 nm lead oxide glass diode laser for MIP in 30 eyes with ME. The study shows that MIP was effective and safe in the treatment of ME, with a high success rate and low recurrence rate. The long-term follow-up results demonstrated the stability of the treatment effect. The authors conclude that MIP is a promising treatment option for ME, and further studies are needed to explore its potential for long-term management of ME.